Adult Dosing
Acute migraine attacks with or without aura
- 20-40 mg PO as a single dose
- May repeat dose after 2 hrs, if headache recurs
- Max: 80 mg/day
Pediatric Dosing
- Safety and effectiveness in pediatric patients have not been established
See Supplemental Patient Information
- Eletriptan should be given only if a clear diagnosis of migraine has been established
- Avoid use of eletriptan within at least 72 hours of treatment with potent CYP3A4 inhibitors
- Eletriptan should not be given when risk factors for coronary artery disease (CAD) are present (e.g. hypertension, hypercholesterolemia, diabetes, smoking, obesity, strong family history of CAD, female with surgical or physiological menopause or male >40 yrs of age) unless a cardiovascular evaluation provides satisfactory clinical evidence that the patient is reasonably free of CAD and ischemic myocardial disease or other significant underlying cardiovascular disease
- Serious adverse cardiac events, including acute MI, arrhythmias, and death, have been reported within a few hours following eletriptan administration
- Sensations of tightness, pain, pressure, and heaviness in the precordium, throat, neck, and jaw have been reported during therapy
- Cardiovascular events may occur in patients without any cardiac history or coronary artery disease. Because of the possibility of coronary vasospasm, patients with signs or symptoms suggestive of angina should be evaluated for the presence of CAD or a predisposition to Prinzmetal’s variant angina before receiving additional doses; monitor ECG if dosing is resumed or symptoms recur
- Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported during therapy and some events resulted to be fatal. Patients with acute migraine may be at increased risk of certain cerebrovascular events (e.g., stroke, hemorrhage, transient ischemic attack)
- Peripheral vascular ischemia and colonic ischemia with abdominal pain and bloody diarrhea have been reported with eletriptan
- Potentially life-threatening serotonin syndrome may occur with co-administration of selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs). Monitor patients for neurologic changes and GI symptoms if concomitant treatment is clinically indicated
- Significant increase in blood pressure have been reported very rarely; contraindicated in patients with uncontrolled hypertension
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- Diabetes mellitus
- Cardiac disease risk
Supplemental Patient Information
- Caution patients about the risk of serotonin syndrome with the use of eletriptan, especially when taken concomitantly with SSRIs or SNRIs
Pregnancy Category:C
Breastfeeding: Although limited data indicates low levels excreted in breast milk, eletriptan would not be expected to cause any adverse effects in infants, especially those older than 2 months. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 17 January 2011). Manufacturer advises caution.
Pricing data from www.DrugStore.com in U.S.A.
- Relpax 40 MG TABS [Box] (PFIZER U.S.)
6 mg = $176.99
18 mg = $512.98 - Relpax 20 MG TABS [Box] (PFIZER U.S.)
6 mg = $176.99
18 mg = $511.97
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
